MAb 002 has shown promise in preclinical models of cancer cachexia, blocking fat and muscle wasting, without inhibiting tumour growth [15]; although the anti-Fn14 antibody can induce tumour growth inhibition in some tumour models (unpublished data). This evidence concerns the gene TNFRSF12A and neoplasm.